Search
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention
Dutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalIt is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. … Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to
Pentastarch
go.drugbank.com/drugs/DB09111ApprovedWithdrawnIt is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation.
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide was approved on April 15, 2014 by the FDA. … It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigational[L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).
Drotrecogin alfa
go.drugbank.com/drugs/DB00055ApprovedWithdrawnDrotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. … It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.
Febuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigational[A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. … Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels.
Verteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet